Decentralized Clinical Trials (DCT) Draft Guidance
U.S. Food and Drug Administration U.S. Food and Drug Administration
165K subscribers
5,889 views
0

 Published On Jul 25, 2023

FDA provides an overview of the draft guidance titled Decentralized Clinical Trials for Drugs, Biological Products, and Devices. FDA experts Discuss topics such as design of a DCT, conduct of remote clinical trial visits and clinical trial-related activities in a DCT, use of digital health technologies to remotely acquire data in a DCT, and roles and responsibilities of the sponsor and investigators in a DCT.

Timestamps

00:56 – Intro - Decentralized Clinical Trials for Drugs, Biological Products, and Devices

04:25 – Overview of the DCT Draft Guidance

30:35 – Q&A Discussion Panel

Speakers:

Leonard Sacks, MBBCh
Associate Director
Clinical Methodologies
Office of Medical Policy (OMP) | CDER | FDA

Ryan Robinson, MD
Medical Officer
Clinical Methodologies
OMP | CDER | FDA

Panelists:

Same as above

Learn more at: https://www.fda.gov/drugs/news-events...

-----------------------

FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2022 Playlist -    • 2022 CDER Small Business and Industry...  
SBIA LinkedIn -   / cder-small-business-and-industry-assistance  
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter -   / fda_drug_info  
Email - [email protected]
Phone - (301) 796-6707 I (866) 405-5367

show more

Share/Embed